Takeda navigates Vyvanse patent cliff with cost cuts, pipeline gains
Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.







_1398976_640x360_2499821123788-640x360.webp&w=3840&q=75)
_1398971_640x360_2499821123516-640x360.webp&w=3840&q=75)
_1398974_640x360_2499822659980-640x360.webp&w=3840&q=75)

_1398970_640x360_2499819587527-640x360.webp&w=3840&q=75)